Accelerated approval of anticancer drugs: a safe choice?
All oncologists know how anxiously cancer patients look forward to the availability in clinical practice of drugs that have yielded positive results in the registration trials. And every year, returning from the annual meeting of the ASCO (American Society of Clinical Oncology), every specialist would like to be able to use immediately that drug or that therapeutic modality that came to the fore at the most important annual congress,